(Albnay, USA) DelveInsight’s Psoriasis Vulgaris Market Insights report proffers a detailed comprehension of the Psoriasis Vulgaris market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Psoriasis Vulgaris market size from 2019 to 2032 segmented into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan).
The Psoriasis Vulgaris market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Psoriasis Vulgaris market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Psoriasis Vulgaris treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Psoriasis Vulgaris market.
Request for sample report @ Psoriasis Vulgaris Market Outlook
Some of the salient features from the Psoriasis Vulgaris Market Report:
For further information on the market impact by therapies, download the Psoriasis Vulgaris sample @ Psoriasis Vulgaris Therapeutic Scenario
Psoriasis Vulgaris Overview
Psoriasis vulgaris, or plaque psoriasis, is a chronic autoimmune skin disorder characterized by red, scaly, and inflamed plaques that commonly appear on the scalp, elbows, knees, and lower back. It occurs when the immune system mistakenly triggers rapid skin cell turnover, causing an excessive buildup of skin cells.
The exact cause remains unknown, but genetics, immune dysfunction, and environmental factors play key roles. Psoriasis vulgaris Triggers include stress, infections, medications (e.g., beta-blockers, NSAIDs), smoking, alcohol, and cold weather.
Common Psoriasis vulgaris symptoms include itching, burning, and skin cracking, which can significantly impact quality of life. Some patients also develop psoriatic arthritis, causing joint pain and stiffness.
Psoriasis vulgaris Treatment options range from topical therapies (steroids, vitamin D analogs), phototherapy, systemic medications (methotrexate, cyclosporine), and biologic drugs targeting inflammatory pathways like TNF-α, IL-17, and IL-23 inhibitors.
While no cure exists, lifestyle modifications, such as moisturizing, stress management, and avoiding triggers, help manage symptoms. Early diagnosis and personalized treatment are crucial for minimizing flares and improving skin health.
For severe cases, biologics have revolutionized treatment, offering long-term control and better patient outcomes. Regular follow-ups with dermatologists and rheumatologists ensure effective disease management.
Psoriasis Vulgaris Epidemiology Segmentation
As per the assessment of DelveInsight, Psoriasis is the most common inflammatory disease in the United States, affecting as many as 8 million Americans and this number is expected to increase during the study period.
As per DelveInsight’s estimates, the total diagnosed prevalent cases of Psoriasis Vulgaris in the US are estimated to be more than 6 million in 2021, the highest among the 7MM and are predicted to increase during the study period (2019-2032).
It is observed that about 80-90% of people living with psoriasis experience Psoriasis Vulgaris and approximately 20% of people suffering from Psoriasis have moderate-to-severe Psoriasis Vulgaris.
The Psoriasis Vulgaris Market report offers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into
Keen to learn how Psoriasis Vulgaris Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Psoriasis Vulgaris Prevalence
Psoriasis Vulgaris Market Outlook
Although Psoriasis Vulgaris cannot be permanently cured, therapeutic interventions for localized Psoriasis Vulgaris should begin with patient education and the use of topical corticosteroids with or without coal tar or calcipotriene. Thereafter, anthralin or tazarotene, alone or in combination with steroids, can be used following first-line treatment failure or subsequent loss of response to first-line therapy. Alternatively, if control is difficult to achieve or disease is widespread, phototherapy, with and without drugs such as psoralen or retinoids, may be required.
There are many FDA-approved Psoriasis Vulgaris treatment therapies available in the market. Some of these include Skyrizi produced by AbbVie which was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults. Ilumya is manufactured by Sun Pharma (also known by its generic name tildrakizumab-asmn), it was FDA approved in March 2018 for moderate-to-severe Psoriasis Vulgaris treatment in adults. Then, Johnson & Johnson’s Psoriasis Vulgaris treatment drug namely Tremfya (also known by its generic name guselkumab) was FDA approved in July 2017. Other FDA-approved and currently marketed Psoriasis Vulgaris treatment drugs include Cimzia by UCB, Inc., Taltz (ixekizumab) by Eli Lilly and Company, and Cosentyx (secukinumab) by Novartis Pharmaceuticals, and Otezla (apremilast) from Amgen.
The dynamics of the Psoriasis Vulgaris market are anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. It includes several Psoriasis Vulgaris pipeline therapies such as DMB-3115, Deucravacitinib, BAT2306, and others under investigation by key Psoriasis Vulgaris market players such as Meiji Seika Pharma, Dermavant Sciences, Bristol-Myers Squibb, Bio-Thera Solutions, Amgen, Arcutis Biotherapeutics, UCB Pharma, and many others.
Discover more about therapy set to grab substantial Psoriasis Vulgaris market share @ Psoriasis Vulgaris Treatment Market
Psoriasis Vulgaris Market Dynamics
DelveInsight’s analysts estimate that the Psoriasis Vulgaris market is poised to show significant growth in the coming years, mainly attributed to increasing cases, recent drug approvals, and the anticipated launch of novel therapies during the forecast period.
Psoriasis Vulgaris Market Driver
Psoriasis Vulgaris Market Barrier
Know which therapy is expected to score the touchdown first @ Psoriasis Vulgaris Market Landscape and Forecast
Scope of the Psoriasis Vulgaris Market Report
Table of Contents
1. Key Insights
2. Report Introduction
3. Psoriasis Vulgaris Market Overview at a Glance
4. Executive Summary of Psoriasis Vulgaris
5. Psoriasis Vulgaris Epidemiology and Market Methodology
6. Psoriasis Vulgaris: Disease Background and Overview
7. Diagnosis of Psoriasis Vulgaris
8. Psoriasis Vulgaris Treatment
9. Conclusion for Psoriasis Vulgaris
10. Psoriasis Vulgaris Epidemiology and Patient Population
11. Psoriasis Vulgaris Patient Journey
12. Key Endpoints in Psoriasis Vulgaris Clinical Trials
13. Psoriasis Vulgaris Marketed Therapies
14. Psoriasis Vulgaris Emerging Therapies
15. Psoriasis Vulgaris: 7 Major Market Analysis
16. Market Access and Reimbursement
17. KOL Views
18. Psoriasis Vulgaris Market Drivers
19. Psoriasis Vulgaris Market Barriers
20. Psoriasis Vulgaris SWOT Analysis
21. Psoriasis Vulgaris Unmet Needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/aacr-annual-meeting
